Blocker-SELEX: a structure-guided strategy for developing inhibitory aptamers disrupting undruggable transcription factor interactions

• Published in: Nature communications Vol. 15; no. 1; pp. 6751 - 17
• Main Authors: Li, Tongqing, Liu, Xueying, Qian, Haifeng, Zhang, Sheyu, Hou, Yu, Zhang, Yuchao, Luo, Guoyan, Zhu, Xun, Tao, Yanxin, Fan, Mengyang, Wang, Hong, Sha, Chulin, Lin, Ailan, Qin, Jingjing, Gu, Kedan, Chen, Weichang, Fu, Ting, Wang, Yajun, Wei, Yong, Wu, Qin, Tan, Weihong
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group 08.08.2024; Nature Portfolio
• Subjects: Aptamers; Blocking; Cell proliferation; Cellular structure; Disruption; Drug discovery; Drug interaction; Gene expression; Internalization; Localization; Molecular structure; Myc protein; Nucleic acids; Pathogenesis; Protein interaction; Proteins; Transcription factors
• ISSN: 2041-1723; 2041-1723
• DOI: 10.1038/s41467-024-51197-w

Despite the well-established significance of transcription factors (TFs) in pathogenesis, their utilization as pharmacological targets has been limited by the inherent challenges in modulating their protein interactions. The lack of defined small-molecule binding pockets and the nuclear localization of TFs do not favor the use of traditional tools. Aptamers possess large molecular weights, expansive blocking surfaces and efficient cellular internalization, making them compelling tools for modulating TF interactions. Here, we report a structure-guided design strategy called Blocker-SELEX to develop inhibitory aptamers (iAptamers) that selectively block TF interactions. Our approach leads to the discovery of iAptamers that cooperatively disrupt SCAF4/SCAF8-RNAP2 interactions, dysregulating RNAP2-dependent gene expression, which impairs cell proliferation. This approach is further applied to develop iAptamers blocking WDR5-MYC interactions. Overall, our study highlights the potential of iAptamers in disrupting pathogenic TF interactions, implicating their potential utility in studying the biological functions of TF interactions and in nucleic acids drug discovery.Transcription factors are crucial in disease but hard to target with traditional drugs. Here, authors present BlockerSELEX, a strategy to develop inhibitory aptamers that block transcription factor interactions, which disrupts interactions between key proteins, showing potential for new nucleic acid therapies.